An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and effectively lower cholesterol levels.

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

Furthermore, AstraZeneca's experimental drug AZD0780 demonstrated promising results in a Phase IIb trial for reducing LDL cholesterol levels, potentially offering a new oral treatment option for ...

AstraZeneca owes Daiichi Sankyo a $125 million milestone payment due to this approval. Furthermore, AstraZeneca's experimental drug AZD0780 demonstrated promising results in a Phase IIb trial for ...

The company said recently it is moving "at pace" with AZD0780 into the next stage of development, with a phase 2b trial ongoing and data expected in the first half of 2025, as it builds a pipeline ...